A Study to Determine the Bioequivalence of Oraxol in Cancer Patients Treated With Intravenous Paclitaxel
A Randomized Crossover Study to Determine the Bioequivalence of Three Consecutive Daily Doses of Oraxol in Cancer Patients Treated With Intravenous Paclitaxel
Sponsor: Athenex, Inc.
Listed as NCT04035473, this PHASE1 trial focuses on Solid Tumor and remains completed. Sponsored by Athenex, Inc., it has been updated 7 times since 2015, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
May 2022 — Jul 2024 [monthly]
Completed PHASE1
-
Jan 2021 — May 2022 [monthly]
Completed PHASE1
▶ Show 2 earlier versions
-
May 2020 — Jan 2021 [monthly]
Completed PHASE1
-
Aug 2019 — May 2020 [monthly]
Completed PHASE1
First recorded
Aug 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Athenex, Inc.
- PharmaEssentia
- Zenith Technology Corporation Limited
For direct contact, visit the study record on ClinicalTrials.gov .